Longitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients

Longitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients - Longitudinal analysis of non-small cell lung cancer-specific immunity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37300

Enrollment

Registered

2012-12-21

Start date

2012-10-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Histologically or cytologically proven irresectable stage III or IV non-small cell lung cancer • Age above 18 years • Performance score: WHO 0, 1 or 2 at the time of study entry • Written informed consent • Specific inclusion criteria for tissue biopsies: - Only target lesion with limited biopsy-procedure related complication risk will be sampled; For instance easily accessible peripheral lymph nodes, subcutaneous, pleural, liver metastastasis. - Other lesions will only be included if there is a clinical necessity for tissue analysis (e.g. molecular profiling, resection metastasis in case of oligometastastic disease). - Only non-irradiated lesions will be sampled

Exclusion criteria

Exclusion criteria: • Severe anemia (Hb

Design outcomes

Primary

Measure	Time frame
The longitudinal effects of treatment for irresectable stage III or IV non-small cell lung cancer on tumor material obtained by surgical removal/biopsies and on peripheral blood components.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results